TRIM29抗体—艾普蒂

+ +

•  

   

     Black line: Control Antigen (100 ng);Purple line: Antigen (10ng); Blue line: Antigen (50 ng); Red line:Antigen (100 ng)    

  
  

•  

   

     Western blot analysis using TRIM29 mouse mAb against Hela (1), HepG2 (2), LOVO (3), and A431 (4) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of Hela cells using TRIM29 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye. Red: Actin filaments have been labeled with Alexa Fluor- 555 phalloidin. Secondary antibody from Fisher (Cat#: 35503)    

  
  

•  

   

     Flow cytometric analysis of HL-60 cells using TRIM29 mouse mAb (green) and negative control (red).    

  
  

The TRIM29 (Tripartite Motif-containing 29) antibody is a tool used to study the TRIM29 protein, a member of the TRIM family involved in diverse cellular processes, including ubiquitination, transcriptional regulation, and DNA repair. TRIM29 contains a conserved N-terminal TRIM motif (comprising RING, B-box, and coiled-coil domains) and a C-terminal PRY/SPRY domain, enabling interactions with other proteins. It has dual roles in cancer, acting as either an oncogene or tumor suppressor depending on tissue context. For example, TRIM29 is upregulated in pancreatic, breast, and prostate cancers, promoting proliferation and metastasis, while downregulated in others, such as bladder cancer, where it may suppress tumorigenesis. Its expression is linked to DNA damage response pathways, immune regulation, and epithelial-mesenchymal transition (EMT).

TRIM29 antibodies are essential for detecting protein expression and localization in cells or tissues via techniques like Western blotting, immunohistochemistry (IHC), and immunofluorescence (IF). These antibodies help elucidate TRIM29's role in disease mechanisms, therapeutic targeting, and biomarker discovery. Commercial TRIM29 antibodies are typically validated for specificity using knockout controls or siRNA-mediated knockdown. Researchers also utilize them to explore TRIM29's interaction partners and post-translational modifications. Due to conflicting roles in different cancers, careful interpretation of TRIM29 expression data is required, emphasizing the antibody's importance in contextual functional studies.